FDA’s Postmarketing Powers Force Shionogi To Withdraw Rybix ODT
This article was originally published in The Pink Sheet Daily
Agency says Shionogi’s orally disintegrating tramadol is misbranded because the firm did not submit a post-marketing trial protocol in time, but the company states the trial is not worth the expense and will withdraw the product.
You may also be interested in...
Januvia and Janumet are misbranded, FDA tells Merck in a warning letter noting that rodent safety studies for the sitagliptin diabetes drugs were 20 months behind schedule. The letter marks the first time FDA has used its FDAAA powers to take enforcement action against a pharma company for such a delay.
Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions without written record; negotiations for BsUFA III may be opportunity to create such a process.